Although ERK1/2, EGFR, or even DDR1 are known as targets to interfere with cancer development and malignancy in oncology for many years, the combined inhibition of these targets offers a novel treatment option in a synergistic manner, especially relevant for TNBC cells. This evidence concerns the gene DDR1 and cancer.